Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
